MIAMI--(BUSINESS WIRE)--Cook Medical’s Zilver PTX Paclitaxel-Eluting Stent (DES) trial results demonstrated no stent fractures. The major adverse event (MAE) rate was equivalent to conventional balloon angioplasty treatment at its six-month follow-up point, as reported by the trial’s national principal investigator today.
